Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

per year."

The phase 2 study enrolled 155 type 2 diabetes patients (51-53 patients/arm) across 50 centers in the United States on a stable treatment regimen of metformin. The study compared six different regimens to find the optimal dose range and regimen to take into phase 3:

  • ITCA 650 20 mcg/day for 24 weeks
  • ITCA 650 40 mcg/day for 24 weeks
  • ITCA 650 20 mcg/day for weeks 1 -12 followed by ITCA 650 60 mcg/day for weeks 13 -24
  • ITCA 650 40 mcg/day for weeks 1 -12 followed by ITCA 650 80 mcg/day for weeks 13 -24
  • Exenatide injection for weeks 1 -12 followed by ITCA 650 40 mcg/day for weeks 13 -24
  • Exenatide injection for weeks 1 -12 followed by ITCA 650 60 mcg/day for weeks 13 -24

  • Summary of week 12 resultsTreatment with ITCA 650 at doses of 20 mcg/day and 40 mcg/day resulted in significant reductions in HbA1c at week 12.  Initiating treatment with ITCA 650 20 mcg/day resulted in less frequent and less persistent nausea compared with ITCA 650 40 mcg/day and exenatide injection.  Nausea rates among patients receiving ITCA 650 at 40 mcg/day were similar to those receiving twice-daily injection of exenatide at 10 mcg BID.

    The phase 2 study also incorporated a quality of life (QOL) assessment (DM-SAT) completed by each patient prior to initiating treatment, at treatment week 8 and again at treatment week 20.  The results of week 8 assessment suggest that patients receiving either dose of ITCA 650 experienced significantly greater improvement in their quality of life compared to patients receiving twice-daily injections of exenatide.

    Summary of week 12 resultsTreatment Arms
    Weeks 1 – 12

    ITCA 650 20 mcg/d

    ITCA 650 40 mcg/dExenatide InjectionMean baseline HbA1c (%)



    8.01Mean week 12 HbA1c (%)



    7.19Mean change



    -0.82*Nausea ratesweek 1



    SOURCE Intarcia Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
    2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
    5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
    8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
    10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
    11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
    Post Your Comments:
    (Date:3/27/2015)... WINNIPEG , March 27, 2015 /PRNewswire/ - Medicure ... Board of Directors has approved the grant of an ... management company employees and consultants of the Company pursuant ... 181,070 are set to expire on the tenth anniversary ... expire on the third anniversary of the date of ...
    (Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
    (Date:3/27/2015)... 27, 2015 Biopharmaceutical Industry Leads Manufacturing ... comes out on top as the country,s manufacturing leader ... report  from ndp│analytics. According to the  analysis , the ... over the last decade, accounting for 27 percent of ... A Short Video on Medicare Part D ...
    Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
    (Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
    (Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
    (Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
    (Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
    (Date:3/28/2015)... Aureus Medical Group (web:, a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
    Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
    ... WASHINGTON , April 18 The Federal Court ... unanimous 3-judge decision,today issued an opinion supporting the ... holding that it is entitled to renew its,constitutional ... Columbia,s AccessRx Act of 2004., Last year, ...
    ... April 18 Breckenridge Pharmaceutical,Inc. announced today that ... approval for the Company,s Abbreviated New Drug Application ... Activella Tablets,(Estradiol/Norethindrone Acetate 1.0mg / 0.5mg) Tablets., ... a,brand product marketed by Novo Nordisk(R), which is ...
    ... result of age, body composition , , FRIDAY, April 18 ... younger age or body composition may not explain why ... of creatinine than white patients, says a U.S. study ... is a standard indicator of kidney function. A higher ...
    ... 18 Sales leaders and,organizations that regularly ... art of motivating their sales representatives. Organizations ... personnel can use the key findings,discovered in ... &,Recognizing Top-Performing Sales People.",( ), ...
    ... ARBOR, Mich. Right now, about half of all people ... help from it. And doctors have no definitive way to ... prescription they write. , But a University of Michigan ... more certainty to how doctors and patients choose anxiety treatments, ...
    ... as much as drug treatments , , FRIDAY, April 18 ... symptoms in patients with terminal cancer, according to Japanese ... included a total of 517 patients with incurable cancer ... treatment for these patients was supportive expressive group therapy, ...
    Cached Medicine News:Health News:PCMA: Court of Appeals Upholds Challenge to D.C.'s PBM Fiduciary-Disclosure Law 2Health News:Muscle Mass May Not Explain High Creatinine in Black Kidney Patients 2Health News:Complementary Excerpt Available from Best Practices: Rewarding and Recognizing Top-Performing Sales People 2Health News:High anxiety? 2Health News:High anxiety? 3Health News:High anxiety? 4Health News:Talk Therapy Proves Effective for Terminal Cancer Patients 2
    IGF-BP3 EIA Endocrine Function 022-IGF-E03 Insulin Growth Factor binding protein...
    ... Angiotensin Converting Enzyme (ACE) is an integral ... the generation of Angiotensin II as well ... many different cell types, ACE is primarily ... only an important diagnostic parameter for sarcoidosis ...
    Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
    ... evaluation of pancreatic -cell function is not only ... of the natural history of diabetes mellitus, but ... guide to the correct choice of treatment. Peripheral ... function because of the large and variable uptake ...
    Medicine Products: